SCHEDULE: Janus Henderson Discloses 9.99% Stake in IMMUNIC, INC.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in IMMUNIC, INC., including common and pre-funded warrants.

Summary

• Janus Henderson Group plc, an investment adviser and holding company, has disclosed a beneficial ownership of 12,016,444 shares of IMMUNIC, INC. common stock.
• This ownership represents 9.99% of the class of securities.
• The reported shares include certain pre-funded and/or common warrants.
• An additional 13,327,439 Series A and 13,327,439 Series B common warrants are not reflected in the reported figures due to a limitation that prevents beneficial ownership from exceeding 9.99% upon exercise.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of IMMUNIC, INC.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant institutional stake. While neutral in tone, the presence of a large, reputable asset manager like Janus Henderson as a major shareholder can be viewed as a moderately positive signal for the company's stability and potential.

Positives

• A significant institutional investor, Janus Henderson Group plc, holds a substantial stake (9.99%) in IMMUNIC, INC., which can be interpreted as a vote of confidence in the company's prospects.
• The investment is stated to be in the ordinary course of business, indicating a long-term investment strategy rather than an activist position.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding IMMUNIC, INC.'s future performance or operations.

Management Comments

• Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group plc, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing represents a standard disclosure of a significant passive investment by a major global asset manager, Janus Henderson Group plc, in a publicly traded company. Such disclosures are common and provide transparency into institutional holdings, which can sometimes signal broader market interest in a particular sector or company.

Stakeholder Impact

• Shareholders may view the significant stake held by Janus Henderson as a positive indicator of institutional confidence in IMMUNIC, INC., potentially influencing market perception and investor sentiment.
• The disclosure provides transparency regarding a major investor's position, which is beneficial for all market participants.

Key Dates

Keywords

IMMUNIC INC, Janus Henderson Group, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investment, SEC Filing